Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.

Trial Profile

Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BRIDGE
  • Most Recent Events

    • 19 Mar 2013 Planned number of patients changed from 3626 to 2526 as reported by ClinicalTrials.gov.
    • 17 Jan 2013 Planned end date changed from 1 Jan 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 13 Feb 2009 Planned initiation date changed from Dec 2008 to May 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top